<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> DOE2-36-0034 </DOCNO><TEXT>F(ab')/sub 2/ fragments of F023C5, an anti-CEA monoclonal antibody, wereconjugated to diethylenetriamine pentaacetic acid (DTPA) and convertedinto a ready to use reagent for instant /sup 111/In-labelling. The resulting/sup 111/In radiopharmaceutical was administered intravenously and testedfor its ability to image (at 48-72 h after administration) 31 primaryand 85 metastatic carcinoma lesions in 70 adenocarcinoma patients (26gastrointestinal, 18 breast and 26 lung tumour patients) whose serumCEA was elevated in 43 cases and normal in the other 27.</TEXT></DOC>